Lipocalin 2 may be a key factor regulating the chemosensitivity of pancreatic cancer to gemcitabine

• Published in: Biochemistry and biophysics reports Vol. 31; p. 101291
• Main Authors: Zhang, He, Wu, Pengpeng, Guo, Chenbo, Zhang, Caiqin, Zhao, Yong, Tan, Dengxu, An, Jiaze, Shi, Changhong
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.09.2022; Elsevier
• Subjects: Chemosensitivity; Gemcitabine; Lipocalin 2; Pancreatic cancer; patient-derived xenografts; Lipocalin 2; Chemosensitivity; Gemcitabine; Pancreatic cancer; patient-derived xenografts

Owing to the high heterogeneity of pancreatic cancer, patient-derived xenografts (PDX) can compensate for the defects of cell line-derived xenografts (CDX) and also better preserve the heterogeneity and tumor microenvironment of primary tumors. Further, gemcitabine, which is used for the treatment o...